MDSpire - MDSpire Home

MDSpire - MDSpire Home

Region

United States US publications and network International Global sites and content

The premier global destination for healthcare professionals looking for trusted clinical content, breaking news, and a wealth of educational resources.

Conexiant.com
Conexiant Education

Trusted by leading healthcare organizations to deliver measurable engagement, education, and brand growth.

Conexiant Solutions
Conexiant DXP

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

MDSpire.com
DentalSpire.com

Association Partner

Our vision is a world free from digestive diseases. That's why it's our mission to empower clinicians and researchers to improve digestive health.

gastro.org
agau.org.gastro
myaga.gastro.org
foundation.gastro.org
agajournals.org
healthecareers.com

Conexiant.com
Conexiant Education

Conexiant DXP

MDSpire.com
DentalSpire.com

gastro.org
myaga.gastro.org
agajournals.org
agau.org.gastro
foundation.gastro.org

Advertisement

What is MDSpire?

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

Learn More

Choose specialties Cardiology Dermatology Endocrinology Family Medicine Gastroenterology Hematology Internal Medicine Neurology ObGyn Oncology Ophthalmology Optometry Pediatrics Rheumatology Pulmonary Psychiatry Pathology Surgery Orthopedic Medicine Radiology Otolaryngology Infectious Disease

April 7, 2026

TTR Amyloidosis: An Underrecognized Disease

April 7, 2026

Dr. Tushak outlines the pathology of amyloidosis, a rare disease characterized by the abnormal deposition of amyloid proteins in tissues and organs. The discuss

...more

Amyloidosis involves abnormal amyloid protein deposition.
Dr. Tushak discusses pathology aspects.
Identification is critical for management.
An algorithm exists for patient screening.
Early diagnosis improves outcomes.
Varied management strategies are needed based on amyloidosis type.
It is classified as a rare disease.

April 7, 2026

Do Women Physicians Leave Practice Earlier Than Men?

Andrea Surnit
April 7, 2026
2 min

A nationwide longitudinal study reveals that female physicians are significantly more likely to leave clinical practice than their male counterparts, with a lik

...more

Female physicians are more likely to leave practice than male physicians.
Median age for female attrition is 49 years; for males, it's 64 years.
Increased attrition rates were observed across urban and rural settings.
Highest attrition rates were in ObGyn and psychiatry.
Study used Medicare data from 2013-
31% of the studied cohort were female physicians.
The findings highlight workforce retention challenges for women in medicine.

The ASCO Post

April 7, 2026

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

The ASCO Post Staff
April 7, 2026
3 min

An analysis by Phesi reveals that 6.7% of active clinical trials are disrupted in the Middle East, impacting 4,361 studies across 186 countries, predominantly a

...more

6.7% of active trials disrupted in the Middle East.
4,361 impacted studies identified.
Turkey, Israel, and Egypt have the most affected sites.
Phase III trials have the highest disruption rate.
Non-small cell lung cancer trials most affected.
Need for data-driven approaches to mitigate risks.
Patient safety remains a top priority.
Large pharmaceutical companies heavily invested in the region.

The ASCO Post

April 7, 2026

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

Matthew Stenger
April 7, 2026
3 min

The phase III KEYNOTE-905/EV-303 trial by Vulsteke et al demonstrated that perioperative enfortumab vedotin and pembrolizumab significantly improved event-free

...more

Phase III KEYNOTE-905/EV-303 trial studied enfortumab vedotin plus pembrolizumab.
Improved event-free survival: 74.7% vs 39.4%.
Overall survival at 2 years: 79.7% for therapy group.
Pathologic complete response: 57.1% in therapy group.
Adverse events significantly higher in therapy group, with urinary infections common.
Funding provided by Merck Sharp and Dohme.
The study indicates safety and efficacy of novel therapy in nearly cisplatin-ineligible patients.

The ASCO Post

April 7, 2026

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

The ASCO Post Staff
April 7, 2026
4 min

Circulating tumor DNA (ctDNA) has shown potential in predicting metastatic risks in muscle-invasive bladder cancer patients, specifically regarding bladder-spar

...more

ctDNA offers insights into metastatic risk in muscle-invasive bladder cancer.
RETAIN trials assess bladder-sparing treatment strategies.
Post-treatment ctDNA negativity predicts metastasis-free outcomes.
RETAIN-2 trials had 80.3% of participants metastasis-free at 29.2 months.
Limitations include challenges in detecting local recurrences.
Future trials aim to refine predictive biomarkers for treatment decision-making.
Importance of active surveillance in managing bladder cancer patients.
ctDNA testing shows promise in personalizing patient care.

The ASCO Post

April 7, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

Jo Cavallo
April 7, 2026
5 min

The combination of enfortumab vedotin-ejfv and pembrolizumab has emerged as the first-line standard treatment for locally advanced or metastatic urothelial carc

...more

Enfortumab vedotin plus pembrolizumab improves survival rates.
Phase III KEYNOTE-B15 study involved 808 patients.
Significant improvement in event-free survival noted.
Pathologic complete response rate higher in treatment group.
Grade ≥ 3 adverse events reported in 75.7% of patients.

April 7, 2026

Flu Vaccination Linked to Lower Heart, Stroke Risk After Infection

Kerri Miller
April 7, 2026
3 min

A nationwide Danish study found that prior influenza vaccination is linked to a significant reduction in the excess risk of acute myocardial infarction and stro

...more

Prior influenza vaccination associated with reduced cardiovascular risk.
Study included 1,221 patients aged 40+.
Highest risk for events within 3 days post-infection.
Vaccinated patients had an adjusted IRR of 2.4 vs 4.7 in unvaccinated episodes.
Majority of infections were influenza A.
The study used a self-controlled case series design for accurate risk assessment.
Limitations include potential underestimation of risk.

Phoenix Children's Medical Connection

April 7, 2026

IPSO Hemorrhagic Stroke Guidelines

April 7, 2026
2 min

The published Hemorrhagic Stroke Guidelines by the International Pediatric Stroke Organization, with contributions from Dr. Janette Mailo of Phoenix Children's

...more

New hemorrhagic stroke guidelines have been published by IPSO.
Dr. Janette Mailo contributed significantly to these guidelines.
Guidelines cover the full spectrum of pediatric intracerebral hemorrhage care.
Part 1 focuses on acute management and decision-making.
Part 2 addresses long-term outcomes and rehabilitation.
Highlights the importance of global consensus for pediatric stroke care.
Phoenix Children’s excels in pediatric care and research.
Emphasizes multidisciplinary approaches for improved outcomes.

April 7, 2026

SaFETy Tool Predicts Firearm Violence Risk

Andrea Surnit
April 7, 2026
3 min

A prospective study led by Jason E. Goldstick, PhD, at the University of Michigan tested a four-item screening tool, the SaFETy score, to assess firearm violenc

...more

SaFETy score predicts firearm violence risk in young adults.
Study involved 1,506 patients aged 18-
Risk rates increased from 2% to 25% across score categories.
Sensitivity: 83%, Specificity: 62% at threshold >
Models with SaFETy score improved risk assessment.
Limitations include self-reported data and sample diversity.
Sponsored by the CDC.
Results may not generalize outside urban EDs.

The ASCO Post

April 7, 2026

Two Major Cancer Centers Announce Appointments of New Directors

The ASCO Post Staff
April 7, 2026
8 min

Dartmouth Cancer Center (DCC) appointed Roy S. Herbst, MD, PhD as its new director to enhance cancer research and treatment efforts starting July 13. Herbst, pr

...more

Roy S. Herbst appointed as director at Dartmouth Cancer Center effective July
Focus on enhancing cancer research and treatment access at DCC.
Robert A. Winn named new director of Fox Chase Cancer Center later this summer.
Dr. Herbst has extensive academic and clinical expertise and aims to integrate efforts across Dartmouth.
Dr. Winn recognized for promoting community engagement in cancer research.
Both directors emphasize advancing cancer care and addressing health disparities.

The ASCO Post

April 7, 2026

Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria

The ASCO Post Staff
April 7, 2026
4 min

Research from the WASHOUT study reveals that 10% of emergency patients with visible hematuria may die within three months. Conducted by Nikita R. Bhatt, the stu

...more

10% of patients with visible hematuria may die within 3 months.
WASHOUT study emphasizes importance of rapid scanning (within 48 hours).
25% of hematuria cases can be linked to cancer, mainly bladder cancer.
Average diagnosis time for patients without tests is 3 weeks.
Prompt scans can reduce mortality and readmission rates.

The ASCO Post

April 7, 2026

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

The ASCO Post Staff
April 7, 2026
3 min

Dr. Matthew R. Zilbelman presented research at the 2026 ASCO Genitourinary Cancers Symposium demonstrating that combining visual inspection of the bladder with

...more

ctDNA tests combined with bladder visual inspection improve cancer detection.
New method achieved 95% accuracy in identifying residual cancer.
It may help avoid unnecessary cystectomy surgeries.
Previous studies indicate significant cancers were missed using standard methods.
Health outcomes improved for patients with negative ctDNA tests.

The Ophthalmologist

April 7, 2026

Haag-Streit Slit Lamp Imaging Competition 2026

April 7, 2026
2 min

Haag-Streit has reopened its annual 'Slit Lamp Imaging Competition,' now in its eighth year, inviting eye care professionals and imaging specialists worldwide t

...more

Haag-Streit has reopened its Slit Lamp Imaging Competition for
The competition is in its eighth year, inviting submissions from global eye care professionals.
Submissions are evaluated on image quality and relevance.
Previous year's winner was Kasi Sandhanam from Singapore.
2026 competition opened on March 30 and closes on July 30,
Winners will be announced on September 30, 2026.

The Ophthalmologist

April 7, 2026

Maternal Diabetes and the Hidden Risk of ROP

April 7, 2026
3 min

Recent research indicates that maternal diabetes during pregnancy is linked to a heightened risk of severe retinopathy of prematurity (ROP) in premature infants

...more

Maternal diabetes increases the risk of severe ROP in premature infants.
Study analyzed 3,100 infants from 2004-
9% of pregnancies had maternal diabetes.
Type 1 diabetes had the strongest link to severe ROP.
Screening could benefit from considering maternal metabolic history.
Higher gestational age and weight seen in infants with maternal diabetes.
Suggests refinement of risk assessment for ROP is needed.

The Ophthalmologist

April 7, 2026

Early Fluid Resolution Predicts Faricimab Durability

April 7, 2026
3 min

A post hoc analysis of the TENAYA and LUCERNE trials investigates the role of early retinal fluid resolution in predicting treatment intervals for patients with

...more

Early resolution of retinal fluid may predict treatment intervals for nAMD.
TENAYA and LUCERNE were phase 3 trials comparing faricimab and aflibercept.
Resolution of intraretinal and subretinal fluid linked to longer dosing intervals.
Faricimab acts on both Ang-2 and VEGF-A.
Higher odds of extended dosing intervals for those with early fluid resolution.
Similar visual outcomes for patients with early resolution.
Potential to reduce treatment burdens on healthcare systems.

April 7, 2026

Hospital-Treated Infections Linked to Dementia Risk

Kathryn Wighton
April 7, 2026
3 min

A Finnish registry study found that hospital-treated cystitis and unspecified bacterial infections are linked to a higher risk of dementia in older patients. An

...more

Cystitis and bacterial infections are linked to increased dementia risk.
Study analyzed 62,555 dementia cases and 312,772 controls.
Infections remained risk factors independent of comorbidities.
Early-onset dementia showed stronger associations with infections.
Comorbidities contributed to 11-14% of the excess dementia risk.
Disease trajectory indicated interconnections between infections and dementia.
The study highlights complex relationships in dementia progression.

April 7, 2026

RA App Overestimates Active Disease

Andrea Surnit
April 7, 2026
3 min

A study led by Dr. Swamy Venuturupalli of Cedars-Sinai Medical Center assessed a smartphone-based app for joint self-assessment in 100 rheumatoid arthritis pati

...more

Smartphone app shows modest agreement with physician joint counts.
High PPV (95%) for identifying low disease activity.
Limited ability to detect active disease (50% NPV).
Patients reported higher joint counts than physicians.
Fibromyalgia and osteoarthritis linked to tender joint counts.
Modest agreement may reflect patient environment and timing issues.

The Medicine Maker

April 7, 2026

Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy

April 7, 2026
2 min

Sartorius has unveiled the Eveo Cell Therapy Platform, a comprehensive manufacturing and quality control system aimed at revolutionizing autologous cell therapi

...more

Sartorius has launched the Eveo Cell Therapy Platform for CAR-T therapies.
The platform enhances manufacturing efficiency and reduces costs.
Enables processing of eight patient batches simultaneously.
Anticipated production cost reduction by 90%.
Orders start in September 2026 with deliveries expected in
ElevateBio is a preferred partner for early access.

Advertisement

Advertisement

Advertisement

About
Privacy Policy

Follow Us